What IRADIMED’s latest dividend and guidance mean for shareholders

IRADIMED (IRMD) has drawn fresh attention after reporting first quarter results, reaffirming its 2026 earnings outlook, and declaring a regular quarterly dividend of $0.20 per share payable on May 29, 2026.

IRADIMED’s latest results and dividend decision have arrived as the share price has eased in recent months, with a 30 day share price return of 7.13% down and a 90 day return of 12.94% down. However, the 1 year total shareholder return of 64.09% and 5 year total shareholder return of 233.30% show longer term holders have still seen very strong gains. This suggests recent weakness may reflect cooler short term sentiment rather than a clear break in the longer term story.

If IRADIMED’s mix of healthcare technology and income appeal has your attention, it can be worth broadening your search with other medical tech opportunities via our 34 healthcare AI stocks

With IRADIMED guiding to full year revenue of $91.0 million to $96.0 million and GAAP EPS of $1.90 to $2.05, and the stock closing at $86.89 against a $118.00 target, investors may be evaluating whether there is still a buying opportunity or whether the market is already pricing in future growth.

Most Popular Narrative: 26.8% Undervalued

IRADIMED's most followed narrative pegs fair value at $118.67 per share, well above the last close of $86.89. This naturally raises questions about what assumptions sit underneath that gap.

The introduction and FDA approval of the new 3870 MRI-compatible IV pump, with significantly enhanced usability and technology over the legacy product, is expected to catalyze a major replacement cycle among hospitals and imaging centers, unlocking large-scale, recurring device and consumable revenues. This supports a step-change in revenue growth as existing customers upgrade and potential new customers previously deterred by usability issues are attracted.

Curious what kind of revenue profile and margin structure could support that higher fair value, and what future earnings power the narrative is baking in? The full story connects procedure volumes, pricing power, and a richer profit mix into one valuation blueprint that is not obvious from the headline numbers.

Result: Fair Value of $118.67 (UNDERVALUED)

However, the story can change quickly if hospitals rein in capital spending or if IRADIMED’s narrow MRI focused product range comes under pressure from new alternatives.

Another angle on valuation

While the analyst narrative suggests IRADIMED is 26.8% undervalued with a fair value of $118.67, the current P/E of 46.2x tells a different story. That multiple is well above the US Medical Equipment industry at 24.1x, the peer average at 36.8x, and the fair ratio of 19.6x, which points to valuation risk if sentiment cools.

For a closer look at how those earnings multiples stack up and what the fair ratio implies for future pricing, review the See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment mixed across valuation signals, it helps to move quickly, check the numbers yourself, and decide what really matters for your portfolio. To see which potential positives are getting investors excited, take a closer look at the 2 key rewards

Looking for more investment ideas?

If IRADIMED has sharpened your focus, now is the time to expand your watchlist and line up a few more stocks that could suit your approach.

• Target resilience by checking out companies flagged in the 67 resilient stocks with low risk scores and see which stocks aim to keep risk scores on the lower side.
• Hunt for potential bargains by scanning the 47 high quality undervalued stocks and spot stocks that pair quality fundamentals with pricing that may not reflect them.
• Strengthen your core holdings by reviewing the solid balance sheet and fundamentals stocks screener (45 results) and focus on businesses that combine financial stability with fundamental support.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.